Somatostatin receptor-targeting peptide

This page covers all Somatostatin receptor-targeting peptide drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Somatostatin receptors.

Targets

Somatostatin receptors

Phase 2 pipeline (1)

• Lu-177 DOTA-TATE · AHS Cancer Control Alberta · Oncology
  Lu-177 DOTA-TATE is a radiolabeled peptide that targets somatostatin receptors on neuroendocrine tumors.